SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following an updated investor presentation highlighting strategic progress, including substantial market share in Japan for its COVID-19 vaccine and the broad potential of its Matrix-M adjuvant. This news, alongside elevated short interest and fervent community discussion around a potential short squeeze, is fueling a market repricing of its protein-based vaccine platform and pipeline assets.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is a major topic of conversation, driven by widespread frustration over its sustained stock decline, which many investors believe contradicts the company's strong fundamentals and recent strategic AI partnerships. Community discussion is heavily focused on how a proposed credit card interest rate cap could significantly boost PayPal's Buy Now, Pay Later segment. This ongoing debate is further fueled by persistent analyst downgrades and calls for management to address the stock's underperformance.

Monero

Monero ($XMR) is surging amid a renewed focus on privacy coins, with the community touting it as the "king of privacy" and the true, untraceable digital cash. Many believe XMR is outperforming competitors like Zcash and even Bitcoin due to its default privacy features, leading to widespread accumulation and ambitious long-term price targets. Despite facing delistings on major exchanges, proponents are actively discussing its fundamental utility and expressing frustration over its lack of trending visibility.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Dow Jones Industrial Average is trending as markets absorb strong anticipation for Federal Reserve interest rate adjustments, contributing to the index reaching all-time highs. Community sentiment leans heavily towards a sustained rally into year-end, driven by hopes of an accommodative monetary policy and robust economic indicators. Conversely, some participants voice concerns over an extended bull run, suggesting the market may be overbought and due for a pullback.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending following strong preliminary revenue results and a record total contract value, driven by rising demand from major pharmaceutical partners for its AI-driven data. Community discussion highlights significant volume and call flows, with traders actively debating its potential for continued growth in precision oncology amid some intraday volatility. The company's strategic partnerships and role in embedding AI into drug discovery and clinical diagnostics are frequently emphasized.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (MLTX) is experiencing significant market attention following positive feedback from the FDA, which confirmed existing trial data is sufficient for a Biologics License Application for its drug sonelokimab in hidradenitis suppurativa, greatly de-risking its regulatory pathway. This development has fueled widespread speculation within the community about potential acquisition bids from major pharmaceutical players like Merck and Eli Lilly, with many investors anticipating a substantial revaluation and a potential short squeeze due to high interest from sellers. The discussion highlights the company's strong asset in the competitive immunology sector and its clearer path to market.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is gaining significant attention following recent company updates confirming it's fully funded for the first quarter with no planned dilution, and highlighting its molecular-level traceability technology for precious metals and anti-counterfeiting. The community is vigorously discussing its strong short squeeze potential, fueled by reports of extremely high Cost-To-Borrow rates and zero available shares, with many anticipating a substantial price surge akin to past low-float runners.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as escalating geopolitical tensions drive a global push for secure rare earth supply chains. China's recent export restrictions on critical minerals and magnets are fueling community discussions about MP's strategic importance as a vertically integrated US producer. Investors anticipate increased focus and potential government-backed initiatives to strengthen domestic rare earth and magnet production for defense, EV, and advanced technology sectors.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is trending as its community enthusiastically locks over 35% of the token supply via the new "AirLock" initiative, fostering robust collective control and strong bullish sentiment. This unique "digital air" asset on Solana, further boosted by a recent celebrity endorsement, is generating significant discussion around its innovative holding mechanism and ambitious goals for widespread exchange listings.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending amid community debate over recent remarks regarding big tech's responsibility for AI data center power costs, with some anticipating increased infrastructure investment and others concerned about financial impacts. Nevertheless, analysts remain bullish on the company's robust AI and cloud monetization as a core beneficiary of the AI supercycle, despite ongoing investor frustration with its subdued price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Salarius Pharmaceuticals (NASDAQ:SLRX) CFO Purchases $16,000.00 in Stock

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX - Get Free Report) CFO Mark Rosenblum purchased 20,000 shares of the company's stock in a transaction on Thursday, November 20th. The stock was purchased...

Penny Stocks To Follow Now - November 12th

Leap Therapeutics, Bitfarms, MSP Recovery, Strive, Salarius Pharmaceuticals, HIVE Digital Technologies, and Beyond Meat are the seven Penny stocks to watch today, according to MarketBeat's stock...

Why Did Salarius (SLRX) Shares Soar Over 23% After-Hours?

Salarius Pharmaceuticals shares jumped 23.7% in after-hours trading Tuesday, closing at $1.21 following its public offering announcement. read more...

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering PR Newswire HOUSTON, Nov...

Salarius Pharmaceuticals’ stock rose 5% after-hours on Monday after announcing it had regained full compliance with all Nasdaq listing requirements, removing the main hurdle to its planned merger with Decoy Therapeutics.The company said Nasdaq informed Salarius on Oct. 10 that it met the equity standard requirement, following an earlier notice in September that it had regained compliance with the minimum bid price rule.Nasdaq notified the company that it will remain under a one-year Mandatory Panel Monitor period through October 2026, during which any violation of equity standards could lead to a delisting notice and hearing process.The merger with Decoy Therapeutics, first announced in January and amended in September, will see Decoy merge into a unit of Salarius, with the combined company operating under the name Decoy Therapeutics. The deal is intended to accelerate the development of peptide conjugate therapeutics through Decoy’s IMP3ACT platform and integrate Salarius’ SP-3164 degrader program.Once complete, the combined company will be led by Decoy’s co-founders, Frederick Pierce and Barbara Hibner, alongside key executives from both firms. Over the next year, Decoy plans to push its lead antiviral drug for coronaviruses closer to FDA review, while also working on new treatments for flu, COVID-19, RSV, and certain gastrointestinal cancers.Salarius, meanwhile, is supporting a clinical study at MD Anderson Cancer Center that’s testing its main drug, seclidemstat, as a possible treatment for serious blood cancers with few existing options.On Stocktwits, retail sentiment for Salarius was ‘bullish’ amid a 5,000% surge in 24-hour message volume.One user said they had added to their Salarius position, citing the company’s low float, full Nasdaq compliance, and solid cash runway.&nbsp;<stembedurl>https://stocktwits.com/Rick2058/message/632179803</stembedurl>Another user noted they felt confident about the stock’s setup, pointing to its low price, small float, and high cost-to-borrow rate, adding that any positive news could send it soaring.<stembedurl>https://stocktwits.com/The_TendieMan_Cometh/message/632144546</stembedurl><a href="https://stocktwits.com/symbol/SLRX">Salarius’ stock</a> has declined 86% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Salarius’ stock (SLRX) has declined 86% so far in 2025. (Photo credit: Getty Images)

Salarius Pharma Stock Jumps After-Hours As Nasdaq Compliance Clears Path For Decoy Merger —  Retail Bulls Bet On Breakout

The company’s move removes the last major hurdle to completing its merger with Decoy Therapeutics, a deal aimed at advancing antiviral and cancer drug programs through Decoy’s IMP3ACT platform.

Equity

Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company that is leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company is headquartered in Cambridge, MA.

Decoy Therapeutics Inc.

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$0.815
Prev Close	$0.8198
Open	$0.831
Dividend Yield	0.00%
50-Day Moving Average	$1.18
Beta	-0.00
Avg. Volume	297,589.82
PE Ratio	-0.02

52-Week High	$52.95
52-Week Low	$0.5148
Market Capitalization	$5.23M
EPS (Annual)	-$86.92
Price to Book	0.18
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

SLRX
Salarius Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLRX News

SLRXSalarius Pharmaceuticals Inc